Cargando…

Calcineurin Inhibitors and COVID-19

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Hage, René, Schuurmans, Macé M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094752/ https://www.ncbi.nlm.nih.gov/pubmed/35568446 http://dx.doi.org/10.1016/j.reumae.2020.09.007

Ejemplares similares

Calcineurin Inhibitors and COVID-19
por: Hage, René, et al.
Publicado: (2022)

Calcineurin inhibitors revisited: A new paradigm for COVID-19?
por: Hage, René, et al.
Publicado: (2020)

Cyclosporine A and COVID-19 – The COQUIMA cohort
por: Schuurmans, Macé M., et al.
Publicado: (2020)

COVID-19-related end stage lung disease: two distinct phenotypes
por: Kostopanagiotou, Kostantinos, et al.
Publicado: (2022)

Suggested management of e-cigarette or vaping product use associated lung injury (EVALI)
por: Hage, René, et al.
Publicado: (2020)

Letter to the editor regarding “The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis”
por: Zhu, Qingcheng, et al.
Publicado: (2022)

Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management
por: Hage, René, et al.
Publicado: (2021)

Adaptive Immunosuppression in Lung Transplant Recipients Applying Complementary Biomarkers: The Zurich Protocol
por: Schuurmans, Macé M., et al.
Publicado: (2023)

Early Use of Rituximab in Calcineurin Inhibitor–Refractory and Steroid-Resistant Nephrotic Syndrome
por: Sinha, Rajiv, et al.
Publicado: (2020)

Calcineurin inhibitor toxicity in a renal transplant recipient
por: Charney, Douglas A., et al.
Publicado: (2009)

Impact of SARS-CoV-2-Related Hygiene Measures on Community-Acquired Respiratory Virus Infections in Lung Transplant Recipients in Switzerland
por: Baumann, Isabelle, et al.
Publicado: (2023)

Calcineurin Inhibitors in Membranous Nephropathy
por: Ponticelli, Claudio, et al.
Publicado: (2021)

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis
por: Rafael-Vidal, Carlos, et al.
Publicado: (2021)

Psychoactive compounds as multifactorial protection factors against COVID-19
por: Javelot, Hervé, et al.
Publicado: (2020)

A polypeptide inhibitor of calcineurin blocks the calcineurin-NFAT signalling pathway in vivo and in vitro
por: Wang, Ping, et al.
Publicado: (2021)

COVID‐19 and (hydroxy)chloroquine–azithromycin combination: Should we take the risk for our patients?
por: Javelot, Hervé, et al.
Publicado: (2020)

Calcineurin-Inhibitor Minimization in Liver Transplant Patients with Calcineurin-Inhibitor-Related Renal Dysfunction: A Meta-Analysis
por: Kong, Yuan, et al.
Publicado: (2011)

Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
por: Bittmann, Stefan, et al.
Publicado: (2020)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Long-term results of a calcineurin inhibitor-free immunosuppression based on Thymoglobulin® and mycophenolate mofetil in elderly kidney transplant recipients
por: Kamar, Nassim, et al.
Publicado: (2008)

Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients
por: Hasbal, Nuri Baris, et al.
Publicado: (2021)

Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection
por: Kemmner, Stephan, et al.
Publicado: (2020)

Calcineurin regulation of cytoskeleton organization: a new paradigm to analyse the effects of calcineurin inhibitors on the kidney
por: Descazeaud, Virginie, et al.
Publicado: (2012)

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination
por: Ivulich, Steven, et al.
Publicado: (2023)

COVID-19 Mortality: The Culprit May Not Be Proton Pump Inhibitors
por: Duan, Zhihui, et al.
Publicado: (2022)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

Treatment of pruritic diseases with topical calcineurin inhibitors
por: Ständer, Sonja, et al.
Publicado: (2006)

Topical calcineurin inhibitors in systemic lupus erythematosus
por: Lampropoulos, Christos E, et al.
Publicado: (2010)

The over-exaggerated chronic nephrotoxicity of calcineurin inhibitors
por: Issa, Naim, et al.
Publicado: (2012)

Calcineurin Inhibitors and Neutropenia: Is Cyclosporine Superior to Tacrolimus?
por: Duggal, Tanu, et al.
Publicado: (2019)

Role of Klotho in Chronic Calcineurin Inhibitor Nephropathy
por: Luo, Kang, et al.
Publicado: (2019)

Old and New Calcineurin Inhibitors in Lupus Nephritis
por: Ponticelli, Claudio, et al.
Publicado: (2021)

COVID-19 and angiotensin-converting enzyme inhibitors from plant origin
por: Gharebaghi, Reza, et al.
Publicado: (2022)

Repurposing Selective Serotonin Reuptake Inhibitors for COVID-19: Rationale and Concerns
por: Navin, Karthick, et al.
Publicado: (2020)

An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19
por: Homolak, Jan, et al.
Publicado: (2021)

Use of SGLT‐2 inhibitor in COVID‐19: A cautionary tale
por: Yousaf, Zohaib, et al.
Publicado: (2021)

Serine protease inhibitors could be of benefit in the treatment of COVID-19 disease
por: Okeahialam, Basil N.
Publicado: (2021)

Aspirin and P2Y12 inhibitors in treating COVID-19
por: Khalaji, Amirmohammad, et al.
Publicado: (2023)

Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19
por: Trojaniello, C., et al.
Publicado: (2021)

Lysosomal chymotrypsin induces mitochondrial fission in apoptotic cells by proteolytic activation of calcineurin
por: Chen, Qianqian, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fm21af65ctp2j9i9lae7eir7nt